AbbVie Inc. €1.4 Billion Senior Notes Offering
Davis Polk advised the underwriters in connection with an SEC-registered offering by AbbVie Inc. of €1.4 billion aggregate principal amount of senior notes in two series, consisting of €750…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Tax counsel to Danaher on the separation and IPO of its dental business
Davis Polk is acting as special tax counsel to Danaher Corporation on the separation of its dental division into a new publicly traded company called Envista Holdings Corporation and the …
PTC Therapeutics, Inc. Concurrent $100 Million Common Stock Offering and $287.5 Million Convertible Senior Notes Offering
Davis Polk advised the underwriter in connection with the SEC-registered offering by PTC Therapeutics, Inc. of 2,475,248 shares of its common stock and the initial purchaser in a concurrent…
Heska Corporation $86.25 Million Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Heska Corporation of an aggregate principal amount of $86.25 million of its 3.750% convertible senior…
iRhythm Technologies, Inc. $115 Million Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with an SEC-registered offering of common stock by iRhythm Technologies, Inc…
Turning Point Therapeutics, Inc. $202.5 Million Follow-On Offering
Davis Polk advised the underwriters in connection with a $202.5 million public offering of common stock by Turning Point Therapeutics, Inc. Turning Point Therapeutics’ common stock is…
Insulet Corporation Convertible Senior Notes Offering
Davis Polk advised the initial purchasers in connection with a Rule 144A offering by Insulet Corporation of $800 million principal amount of 0.375% convertible senior notes due 2026,…
Deciphera Pharmaceuticals Follow-On Offering
Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds…
Portola Pharmaceuticals, Inc. Follow-On Offering
Davis Polk advised the joint book-running managers and the lead manager in connection with a $258.8 million public offering of common stock by Portola Pharmaceuticals, Inc. The common stock…
Stemline Therapeutics, Inc. Common Stock Offering
Davis Polk advised the underwriters in connection with the SEC-registered offering of 5,750,000 shares of common stock of Stemline Therapeutics, Inc. for total gross proceeds of…